13F Holdings
中文EN

NIVF NewGenIvf Group Ltd Annual reports only

Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1981662

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-13.0%
TTM net income YoY1,983.1%
TTM EPS YoY100.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR178.2%

Margins

Gross margin20.2%
Operating margin-226.9%
Net margin209.0%
FCF margin-234.0%
EBITDA margin-223.0%

Returns

ROE77.2%
ROA54.4%
ROIC (approx.)-88.0%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.12x
Interest coverage-17.40x

Cash quality & payout

Operating cash flow / net income-1.11x
Accruals ratio114.6%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.73M$5.43M$5.14M$5.94M$4.12M
Cost of revenue$3.77M$3.61M$3.45M$4.41M$3.09M
Gross profit$955,846$1.83M$1.68M$1.54M$1.02M
SG&A expense$10.49M$2.78M$1.62M$1.10M$801,329
Operating income-$10.73M-$1.16M$42,242$398,705$198,758
Interest expense$616,423$765,177$46,179——
Pretax income$9.73M-$960,807$108,418$343,988$156,184
Income tax—-$486,706—$208,141$294,716
Net income$9.88M-$524,643$130,193$458,667-$533
EBITDA-$10.54M-$1.14M$73,415$499,238$365,467
EPS (basic)214.73-4,408.7613,019.304.720.00
EPS (diluted)3.04-4,408.7613,019.304.720.00
Weighted avg. shares (diluted)3.25M1191028,797560,000
Banking
Provision for credit losses—$17,818———
Balance sheet
Cash & equivalents$758,621$457,740$54,104$27,556$28,764
Receivables$166,531$49,245$9,374$13,000—
Inventory$335,360$80,813$126,264$46,910—
Current assets$7.38M$3.17M$2.46M$2.40M—
PP&E, net$1.79M$273,096$162,157$122,673—
Intangibles$21.42M————
Total assets$32.72M$3.58M$4.49M$2.90M—
Current liabilities$2.37M$2.72M$1.12M$2.56M—
Total liabilities$6.74M$5.06M$1.24M$2.80M—
Shareholders' equity$26.63M-$1.05M$3.74M$563,113-$914,910
Shares outstanding240,622380507,469601,830—
Cash flow statement
Operating cash flow-$10.93M-$8.26M-$1.77M$1.71M$1.43M
Capital expenditure$135,025$53,045$69,848$94,452$16,575
Free cash flow-$11.06M-$8.32M-$1.84M$1.62M$1.42M
Investing cash flow-$7.56M-$53,045-$69,848-$94,452-$16,575
Financing cash flow$18.99M$8.68M$1.88M-$1.63M-$1.54M
Depreciation & amortization$188,109$19,502$31,173$100,533$166,709
Stock-based compensation———$240,000$200,000

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.